(Q39547659)

13 September 2017

title

Quinacrine has anticancer activity in breast cancer cells through inhibition of topoisomerase activity (English)

1 reference

13 September 2017

1 reference

Ranjan Preet

1

0 references

Michael D Wyatt

object named as

Michael D Wyatt

6

0 references

author name string

Purusottam Mohapatra

2

1 reference

13 September 2017

Suchitra Mohanty

3

1 reference

13 September 2017

Sushil Kumar Sahu

4

1 reference

13 September 2017

Tathagata Choudhuri

5

1 reference

13 September 2017

Chanakya Nath Kundu

7

1 reference

13 September 2017

language of work or name

English

0 references

publication date

16 August 2011

1 reference

International Journal of Cancer

13 September 2017

published in

1 reference

13 September 2017

volume

130

1 reference

13 September 2017

issue

7

1 reference

13 September 2017

page(s)

1660-1670

1 reference

New hopes from old drugs: revisiting DNA-binding small molecules as anticancer agents

13 September 2017

cites work

1 reference

Drug targets and mechanisms of resistance in the anaerobic protozoa

21 January 2018

1 reference

The use of quinacrine (Atabrine) in rheumatic diseases: a reexamination

21 January 2018

1 reference

Interstitial quinacrine for elimination of abnormal tissue; therapy of experimental glioma.

21 January 2018

1 reference

Interest of acridine derivatives in the anticancer chemotherapy

21 January 2018

1 reference

Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-kappaB-dependent mechanism of p53 suppression in tumors

21 January 2018

1 reference

Chloroquine potentiates the anti-cancer effect of 5-fluorouracil on colon cancer cells

21 January 2018

1 reference

Acridine-based agents with topoisomerase II activity inhibit pancreatic cancer cell proliferation and induce apoptosis

21 January 2018

1 reference

Inhibition of NF-kappaB signaling by quinacrine is cytotoxic to human colon carcinoma cell lines and is synergistic in combination with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) or oxaliplatin

21 January 2018

1 reference

Deficient TP53 expression, function, and cisplatin sensitivity are restored by quinacrine in head and neck cancer

21 January 2018

1 reference

Enhancement of paclitaxel activity against hormone-refractory prostate cancer cells in vitro and in vivo by quinacrine

21 January 2018

1 reference

Therapy of glioblastoma multiforme improved by the antimutagenic chloroquine

21 January 2018

1 reference

9-Aminoacridine-based anticancer drugs target the PI3K/AKT/mTOR, NF-kappaB and p53 pathways

21 January 2018

1 reference

Quinacrine enhances cisplatin-induced cytotoxicity in four cancer cell lines.

21 January 2018

1 reference

Anti-malaria drug blocks proteotoxic stress response: anti-cancer implications

21 January 2018

1 reference

Novel acridine-based compounds that exhibit an anti-pancreatic cancer activity are catalytic inhibitors of human topoisomerase II.

21 January 2018

1 reference

Single cell gel/comet assay: guidelines for in vitro and in vivo genetic toxicology testing

21 January 2018

1 reference

Molecular targets of dietary agents for prevention and therapy of cancer

21 January 2018

1 reference

p53 pathway in renal cell carcinoma is repressed by a dominant mechanism.

21 January 2018

1 reference

Re-evaluation of the mutagenic potential of quinacrine dihydrochloride dihydrate

21 January 2018

1 reference

Evolution and Prevention of Drug-Resistance

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/IJC.26158

1 reference

13 September 2017

1 reference